Articles related to DRUG REPURPOSING

A patient with advanced, treatment-resistant lung cancer experienced complete tumor disappearance after sodium selenite treatment and remained tumor-free for 10 years. The single case cannot establish efficacy, safety, or causality.

Two phase 3 trials found upadacitinib increased scalp, eyebrow, and eyelash regrowth in adolescents and adults with severe alopecia areata. Longer-term safety, durability, and regulatory review remain important considerations.

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

The reseachers acknowledge that the Delphi approach favors compounds already studied and may exclude agents identifiable only through high-throughput screening.

“Too many neurons go astray, and that’s when you get amyloid-beta production. And then it’s tau, and then it’s dead cells, then dementia — and then it’s too late.” — Jeffrey Savas, Northwestern University

In neuro-oncology, where many of the therapies are expensive, toxic, and difficult to access, the idea that a low-cost, generic medication might help slow a tumor like glioblastoma is extremely attractive.